Aug 05, 2021 8:00am EDT Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”
Jul 26, 2021 8:00am EDT Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development
Jul 08, 2021 8:00am EDT Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection
Jul 01, 2021 4:39pm EDT Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021
Apr 29, 2021 8:00am EDT Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
Feb 18, 2021 7:30am EST Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer
Dec 31, 2020 8:00am EST Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Secures $60 Million Capital Commitment From Global Emerging Markets